{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:11:37Z","timestamp":1745554297942,"version":"3.40.4"},"reference-count":4,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Res Paediatr"],"published-print":{"date-parts":[[2004]]},"abstract":"<i>Objectives:<\/i> To compare the effects of vitamin D analogs versus calcitriol on serum levels of Ca, P and parathyroid hormone (PTH). A compound better than calcitriol should increase the Ca x P product less than calcitriol for an equivalent decrease in PTH levels. <i>Methods:<\/i> Biological activity of 4 vitamin D analogs, 1,25-(OH)<sub>2<\/sub>-16ene- D<sub>3<\/sub> (RO<sub>1<\/sub>), 1,25-(OH)<sub>2<\/sub>-16ene-23yne-D<sub>3<\/sub> (RO<sub>2<\/sub>), 1,25-(OH)<sub>2<\/sub>-26,27-hexafluoro-16ene-23yne-D<sub>3<\/sub> (RO<sub>3<\/sub>) and 1,25-(OH)<sub>2<\/sub>-16ene-23yne-26,27-hexafluoro-19nor-D<sub>3<\/sub> (RO<sub>4<\/sub>) was tested vs. calcitriol in parathyroidectomized rats. In a second set of experiments, the effects of RO<sub>2<\/sub>, RO<sub>4<\/sub> and calcitriol were studied in 5\/6 nephrectomized rats with secondary hyperparathyroidism. <i>Results:<\/i> In parathyroidectomized rats, all analogs (250 pmol\/day) led calcemia to rise after 7 days. In uremic rats, all treatments reduced PTH levels. RO<sub>4<\/sub> revealed toxicity. RO<sub>2<\/sub> was as effective as calcitriol in suppressing PTH in a dose dependent manner. Mean plasma ionized calcium did not change from baseline to day 14 and day 28 on RO<sub>2<\/sub> (250 or 500 pmol\/day) whereas it increased significantly on RO<sub>2<\/sub> (1,000 pmol\/day) and calcitriol (125 or 250 pmol\/day). Increasing the dose of calcitriol led Ca \u00d7 P to rise more dramatically than increasing the dose of RO<sub>2<\/sub>, which appears to have a wider therapeutic window than calcitriol. <i>Conclusion:<\/i> 1,25-(OH)<sub>2<\/sub>-16ene-23yne-D<sub>3<\/sub> (RO<sub>2<\/sub>) may represent a novel candidate for the treatment of renal osteodystrophy in humans.<\/jats:p>","DOI":"10.1159\/000075191","type":"journal-article","created":{"date-parts":[[2003,12,19]],"date-time":"2003-12-19T09:25:47Z","timestamp":1071825947000},"page":"7-16","source":"Crossref","is-referenced-by-count":4,"title":["1,25-(OH)<sub>2<\/sub>-16ene-23yne-D<sub>3<\/sub> Reduces Secondary Hyperparathyroidism in Uremic Rats with Little Calcemic Effect"],"prefix":"10.1159","volume":"61","author":[{"given":"Kurt","family":"Lippuner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Perrelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Casez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Popp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan R.","family":"Uskokovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,3,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330307"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5333.1827"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.49.1.15"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0955-2863(93)90020-W"}],"container-title":["Hormone Research in Paediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/75191","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/75191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:59:56Z","timestamp":1745467196000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000075191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":4,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000075191","archive":["Portico"],"relation":{},"ISSN":["1663-2818","1663-2826"],"issn-type":[{"type":"print","value":"1663-2818"},{"type":"electronic","value":"1663-2826"}],"subject":[],"published":{"date-parts":[[2004]]}}}